Jubilant Pharmova Block Deal: Quant Mutual Fund Sells ₹190 Crore Stake As Company Plans ₹800 Crore Fundraising
Add Preferred News Source
Quant Mutual Fund sold ₹190 crore worth of Jubilant Pharmova shares, while Abakkus bought 11 lakh shares. The company also approved plans to raise ₹800 crore through NCDs.
Quant Mutual Fund sold 20.81 lakh shares of Jubilant Pharmova for approximately ₹190.47 crore through bulk deals on Monday, 12 October. Abakkus Four2Eight Opportunities Fund purchased 11 lakh shares in a transaction worth ₹100.65 crore. The deals took place as the pharmaceutical company announced plans to raise up to ₹800 crore through non-convertible debentures (NCDs).
Quant Mutual Fund Sells Shares; Abakkus Buys 11 Lakh Shares
Quant Mutual Fund sold 11 lakh shares on the National Stock Exchange (NSE) at ₹915 per share. The transaction was valued at ₹100.65 crore. It also sold 9,81,704 shares on the Bombay Stock Exchange (BSE) at ₹915.01 apiece, generating approximately ₹89.82 crore.
Abakkus Four2Eight Opportunities Fund bought 11 lakh shares at ₹915 each on the NSE. The purchase was worth ₹100.65 crore. According to the June 2026 shareholding data, Quant Small Cap Fund held a 1.85% stake in Jubilant Pharmova.
Jubilant Pharmova shares closed 2.04% higher at ₹950.90 on the NSE on Monday. The stock traded between ₹908 and ₹969.90 during the session. Despite the day's gains, it remained down 8.80% so far in 2026. The company's market capitalisation stood at approximately ₹15,146 crore.
Jubilant Pharmova Approves ₹800 Crore NCD Issue
Jubilant Pharmova's board has approved the issuance of up to 80,000 NCDs, each carrying a face value of ₹1 lakh. The proposed issue amounts to ₹800 crore and will be conducted through private placement in one or more tranches, subject to applicable requirements and approvals.
The board has also approved seeking shareholder authorisation to issue debt securities through private placement. The proposed limit is ₹2,500 crore in aggregate outstanding borrowings at any point during the one-year period following the resolution's approval.
The fundraising plan and the block deals are separate developments. Investors will be watching how the proposed debt issuance affects the company's financing plans and how institutional shareholding changes following the transactions.
Also Read - Stocks To Watch Today: RBL Bank, HCL Tech, ICICI Pru AMC And More On 13 October 2026
This article is for informational purposes only and should not be considered investment advice from Kotak Neo. For compliance T&C and disclaimers, Visit www.kotakneo.com/disclaimer
Vishwa has spent 10+ years across fintech and FMCG doing what most people miss, connecting the dots, catching trends before they trend, and finding the angle nobody else thought to ask about.
At Kotak Neo, she drives content strategy for neoshorts, Kotak News Desk, and Investing Guide, turning market noise into something worth reading.
When she's not decoding markets, she trades charts for canvases, chasing art, painting, and architecture across cities she's yet to explore.
Right Tools, Rich Insights
